MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Erausquin, G. A.
Right arrow Articles by Dugan, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Erausquin, G. A.
Right arrow Articles by Dugan, L. L.

Vol. 63, Issue 4, 784-790, April 2003


Nuclear Translocation of Nuclear Transcription Factor-kappa B by alpha -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors Leads to Transcription of p53 and Cell Death in Dopaminergic Neurons

Gabriel A. de Erausquin, Krzyztof Hyrc, David A. Dorsey, Daniel Mamah, Mehmet Dokucu, Daniel H. Mascó, Timothy Walton, Krikor Dikranian, Mario Soriano, José Manuel García Verdugo, Mark P. Goldberg, and Laura L. Dugan

Departments of Psychiatry (G.A.d.E., D.A.D., D.M., M.D., K.D.) and Neurology (G.A.d.E., T.W., M.P.G., L.L.D.) and Center for the Study of Nervous System Injury (G.A.d.E., K.H., M.P.G., L.L.D.), Washington University School of Medicine, St. Louis, Missouri; Departamento de Farmacología, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina (D.H.M.); and Departamento de Biología Celular, Universidad de Valencia, Valencia, Spain (M.S., J.M.G.V.)

    Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

We describe a new molecular mechanism of cell death by excitotoxicity mediated through nuclear transcription factor kappa B (NFkappa B) in rat embryonic cultures of dopaminergic neurons. Treatment of mesencephalic cultures with alpha -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) resulted in a number of changes that occurred selectively in dopaminergic neurons, including persistent elevation in intracellular Ca2+ monitored with Fura-2, and a significant increase in intramitochondrial oxidation of dihydrorhodamine 123, probably associated with transient increase of mitochondrial permeability, cytochrome c release, nuclear translocation of NFkappa B, and transcriptional activation of the oncogene p53. Interruption of any of these steps by specific antagonists prevented neurite pruning and programmed cell death. In contrast, cell death was not prevented by caspase antagonists and only partly prevented by nitric-oxide synthase inhibitors. This signal transduction pathway might be a contributing mechanism in ongoing neuronal death in Parkinson disease.

    Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Parkinson disease (PD) is among the most prevalent neurological disorders in the elderly, and loss of mesencephalic dopaminergic neurons (DNs) is considered the cause of the motor symptoms of the illness. The reasons for the selective susceptibility of DNs in PD are poorly understood. Experimental and pathological data implicate a susceptibility of DNs to oxidative stress triggered by endogenous or exogenous toxins. Oxidative stress has been demonstrated in brain and in cell models of PD (Cassarino et al., 2000). In late stages of PD, the substantia nigra exhibits increased lipid peroxidation, superoxide dismutase activity, and iron content, and glutathione levels are decreased, very likely favoring oxidative stress (Hirsch et al., 1991; Jellinger et al., 1993). DNs may display an increased susceptibility to premature death because of poor calcium (Ca2+) homeostasis (de Erausquin et al., 1994), insufficient Ca2+ buffering by Ca2+ binding proteins (German et al., 1992; Damier et al., 1999), increased requirement for trophic factor support, and abnormal proteosome degradation (McNaught and Jenner, 2001). In late PD stages, there is evidence of apoptosis (Mochizuki et al., 1996; Anglade et al., 1997), but other forms of cell death may also play a role (Jellinger, 2001). Direct damage to macromolecules by lipid peroxidation (Jenner, 1998) or release of tumor necrosis factor alpha  (TNFalpha ) by microglia (Hunot et al., 1997; Hartmann et al., 2002) has been suggested. Transcription factor NFkappa B nuclear translocation---which may be triggered by TNFalpha ---is found during post-mortem examination to be increased in brains of persons with PD (Hunot et al., 1997). The relevance of this mechanism in PD was questioned (Jellinger, 2001), in part because NFkappa B is neuroprotective in other neuronal phenotypes (Mattson et al., 2000).

To elucidate the mechanism of susceptibility of DNs, we studied cultures of mesencephalon, which allow in vitro comparisons of individual DNs with neurons expressing other phenotypes. In this system, DNs show unique physiologic properties---compared with nondopaminergic neurons---and, like DNs in vivo (Bywood and Johnson, 2000), are selectively susceptible to GluRAMPA receptor agonists (de Erausquin et al., 1994; Isaacs et al., 1996). DN susceptibility to GluRAMPA agonist toxicity is phenotype-specific, because other neuronal phenotypes in vitro display trophic responses or physiologic effects, but not toxicity (de Erausquin et al., 1994; Isaacs et al., 1996). After treatment with (S)-alpha -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), DNs selectively display [Ca2+]i accumulation, either because DNs lack adequate [Ca2+]i buffering capacity (Isaacs et al., 1996), because they have larger functionally available [Ca2+]i stores (de Erausquin et al., 1994), or both. We tested the hypothesis that AMPA-induced injury to DNs is mediated through activation of the reactive oxygen species (ROS)-sensitive transcription factor NFkappa B and the oncogene p53; we postulate that this signaling pathway could account for the increased NFkappa B translocation observed post-mortem in PD.

    Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Experimental Procedures and Immunohistochemistry

Cultures. Cultures were prepared as described previously (de Erausquin et al., 1992). Briefly, ventral mesencephali from day 15 rat embryos (Sprague-Dawley timed mothers; Charles River Laboratories, Wilmington, MA) were mechanically dissociated and plated at a density of 30 to 50,000 cells/cm2 on dishes or multiwell plates coated with 15 mg/ml poly(D-lysine) (Mr 53,000; Sigma, St. Louis, MO) and 10 mg/ml laminin (Sigma). The culture medium contained Dulbecco's modified Eagle's medium/Ham's F12 medium (50%/50%) (Invitrogen, Carlsbad CA), 25 mM glucose, 2 mM glutamine, 10% horse serum (Hyclone, Logan, UT), bFGF (10 ng in 500 ml; Sigma), and insulin-transferrin-sodium selenite media supplement (Sigma). Cells were cultured 9 days at 37°C in an atmosphere of 95% air/5% CO2 saturated with H2O.

AMPA Toxicity. Culture medium was exchanged with conditioned medium containing 10, 30, or 100 µM AMPA alone or in combination with drugs (Isaacs et al., 1996). Cells were then returned to the incubator for the length of the experiment (24 h for viability). Drugs were dissolved in HEPES-buffered saline solution (116 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO4, 1.8 mM NaH2PO4, 12 mM HEPES, 25 mM NaHCO3, and 5.5 mM D-glucose, pH 7.4).

Immunohistochemistry. Cultures were fixed in phosphate-buffered saline containing 4% paraformaldehyde and 0.5% glutaraldehyde for 30 min at room temperature; permeabilized in 0.25% Triton X-100 for 10 min; blocked in 10% goat serum; and incubated in primary antibody, followed by conjugated secondary antibody (Alexa-488 or Alexa-568; Molecular Probes, Eugene, OR). Monoclonal or polyclonal antibodies were from commercial sources: tyrosine hydroxylase (TH; Pelfreeze, Rogers, AK; or Chemicon, Temecula, CA), MAP2 (Roche Molecular Biochemicals, Indianapolis IN), synapsin-1 (Chemicon), Ikappa Balpha (Abcam, Cambridge, UK), NFkappa Bp65 (Santa Cruz Biotechnologies, Santa Cruz, CA), cytochrome c (BD Biosciences PharMingen, San Diego, CA), phosphoprotein p53 (phos-p53; Zymed, South San Francisco, CA).

Neuronal Survival. Cultures immunostained with microtubule associated protein 2 (MAP2) and TH were counted. The number of fields required to count 1000 cells on control wells (typically 52 fields at 200×) was matched in experimental wells. Values represent averages of at least three experiments.

Neurite Morphology. Digital images of DNs were captured with a cooled charge-coupled device camera (Nikon Diaphot, Nikon Apo 20× dry objective; Nikon, Tokyo, Japan), and analyzed (MetaMorph; Universal Imaging, WestChester, PA). Cell process number, length, and branch frequency were counted; lengths were measured in pixels, transformed to micrometers using standard rulers, and averaged for each cell.

Electron Microscopy. Cultures were fixed, stained with immunoperoxidase-diaminobenzidine, dehydrated, embedded in an epon/araldite mix, and cut for light (1.0 µm) or electron microscopy (EM) (80 nm). For EM (Philips EM300 TEM), sections were mounted on copper grids and stained with uranyl acetate and lead citrate. DNs were identifiable by the presence of the chromogen.

Identification of DNs. DNs were distinguished by uptake of 5,7-dihydroxitryptamine (5,7-DHT) by briefly viewing cultures under fluorescence (excitation, 360 nm; emission, 420 nm; Silva et al., 1988; de Erausquin et al., 1992); phase contrast was used to allow relocation. Rapid bleaching of 5,7-DHT prevented interference with further imaging.

DHR123 Fluorescence. Cultures incubated with dihydrorhodamine 123 (DHR123) were imaged using a laser scanning confocal microscope (Noran Odyssey equiped with an argon-ion laser; excitation, 488 nm; emission, 515 nm) coupled to an inverted microscope (Nikon Diaphot; 60× oil immersion objective Nikon Plan Apo) (Dugan et al., 1995). Frame-averaged images were analyzed using regions of interest (MetaMorph). All drugs were added in a small aliquot of buffer (50 µl).

NFkappa B Activation

Nuclear Extracts. Experiments were terminated with iced lysis buffer [10 mM KCl, 1.5 mM MgCl2, 0.5 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 10 mM HEPES, pH 7.9, plus 2 mg/ml pepstatin A, 2 mg/ml leupeptin, and 2 mg/ml L-leucinethiol]. Samples were homogenized, incubated on Nonidet P-40, and centrifuged. Pellets were resuspended in extraction buffer (420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, and 20 mM HEPES, pH 7.9, plus 2 mg/ml pepstatin A, 2 mg/ml leupeptin, and 2 mg/ml L-leucinethiol) and centrifuged for 15 min at 12,500 rpm (4°C). The supernatant containing the nuclear extracts was saved, and protein concentration determined (Invitrogen).

Electrophoretic Mobility Shift Assay. EMSAs were performed using a commercially available kit (Boehringer Ingelheim, Petersburg, VA). Aliquots incubated 15 min with 1 × 105 cpm of 32P-end-labeled, double-stranded oligonucleotide (5'-TCAGAGGGGACTTTCCGAGAGG-3') were run on 6% polyacrylamide gels for 105 min with 150 V (reaction buffer, 500 mM NaCl, 5 mM EDTA, 5 mM DTT, 50 mM Tris, pH 7.5, 20% glycerol, 0.4 mg/ml salmon sperm DNA). Specificity was determined by adding a 100-fold excess of unlabeled competitor DNA to the reaction. For gel supershift analysis, nuclear proteins were incubated with antibodies against p65 protein, and gel-shift analysis was performed after adding labeled oligonucleotide.

ELISA. Aliquots were transferred to 96-well plates containing high-density immobilized oligonucleotide (5'-GGGACTTTCC-3') (Trans-AM's ELISA; Active Motif, Carlsbad, CA). Anti-IgG HRP-conjugate and developing solution were added and read by spectrophotometry.

Western Blot. Cultures were lysed, and run on standard polyacrylamide gels, transferred to a nitrocellulose membrane, incubated in primary IgG antibody (1:1000), washed, incubated in alkaline phosphatase-linked secondary IgG antibody (1:2000), and imaged by chemiluminescence.

Reverse Transcriptase-PCR. Total RNA was prepared using TRIzol reagent (Invitrogen) and enriched for mRNA by an oligo(dT) spin-column kit (Oligotex; QIAGEN, Valencia, CA). mRNA was spectrophotometrically quantified and 40 ng of mRNA per reaction was used to synthesize first-strand cDNA (SuperScript RT-PCR System; Invitrogen). Semiquantitative PCR reaction aliquots were run on agarose and stained with ethidium bromide. PCR was performed for 28 and 30 cycles (1 min at 94°C, 1 min at 55°C, and 1 min at 72°C). Thirty cycles saturated the reaction. Duplicates of 28 cycle reactions were consistent with each other and were used for the results shown here. Primer sequences were: cyclophilin 5'-ATGGTCAACCCCACCGTGTT, cyclophilin 3'-CGTGTGAAGTCACCACCCT, p53left-TGAGCATCGAGCTCCCTCTG, and p53right- CACAGGCCTCAGCTGGGATAGCACCTC.

Drugs. AMPA and N-methyl-D-aspartic acid were from Tocris Cookson Inc. (Ballwin, MO). Dizocilpine maleate, 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX), 1-napthyl-acetyl spermine trihydrochloride (NAS), N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone, cyclosporin A (CSA), 1-[bis(p-chlorophenyl)methyl]-3[2,4-dichloro-beta -(2,4-dichlorobenzyloxy) phenethyl]-imidazolium chloride, 2,6-dimethyl-4-(2'-nitrophenyl)-3,5-pyridinecarboxylic acid dimethyl ester, and sodium 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (DEA/NO) were from Sigma-RBI (Natick, MA). 5,7-DHT, DTT, PMSF, and pyrrolidine dithiocarbamate (PDTC) were from Sigma-Aldrich (St. Louis, MO). DHR123 was from Molecular Probes (Eugene, OR). Boc-aspartyl-(OMe)-fluoromethyl ketone was from Enzyme Systems Products (Livermore, CA). Tacrolimus was from Fujisawa USA (Deerfield, IL). The HPNFkappa B oligonucleotide sequence (5'-AGTTGAGGGGACTTTCCCAGGC-3') and C-NFkappa B oligonucleotide sequence (5'-CTAATCTCCTCTAATCTCCCT-3') were from the Nucleic Acid Chemistry Laboratory, Biotechnology Center, Washington University, (Saint Louis, MO).

    Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Morphological Characteristics of DNs Undergoing AMPA Toxicity. Treatment with AMPA for 24 h caused concentration-dependent death of DNs (EC50 approx  30 µM), without significant change in MAP2-stained/TH-negative neurons (Fig. 1a). N-Methyl-D-aspartic acid (100-300 µM) failed to affect survival, and 3 µM dizocilpine failed to protect against AMPA toxicity (not shown). Surviving DNs showed neurite pruning, even after 10 µM AMPA (control, 1265 ± 109 µm; treated, 773 ± 81 µm). This AMPA concentration failed to elicit significant cell loss (Fig. 1, a and b). AMPA-induced pruning (shortening of neurites with loss of dendritic branching) (Fig. 1, c and d), was associated with loss of characteristic punctate synapsin staining along the neurites of DNs (Fig. 1, e and f). Ultrastructural analysis of DNs after 30 µM AMPA administration revealed nuclear invagination and irregular aggregation of chromatin consistent with excitotoxicity (Fig. 1, g-h) (Ishimaru et al., 1999).


View larger version (93K):
[in this window]
[in a new window]
 
Fig. 1.   Selective susceptibility of DNs to AMPA toxicity. Cultures were treated for 24 h with conditioned medium alone (control) or with 10, 30, or 100 µM AMPA. AMPA caused a loss of TH-stained neurons without significant change in MAP2-stained counts (a) (**, p < 0.01 compared with control). In TH-stained neurons, a concentration-dependent pruning is readily observed (b) (*, p < 0.05 compared with control). Examples of control (c) and 30 µM AMPA (d) are shown. About 50% of surviving treated DNs showed the changes demonstrated in d; the remainder showed varying degrees of pruning. Double staining with TH (green) and synapsin I (red) in control (e) and treated (f) cultures reveals loss of characteristic puncta in DNs after 30 µM AMPA treatment for 24 h; examples were chosen for their morphological integrity. Electron micrographs of DNs stained with TH/diaminobenzidine after 30 µM AMPA treatment for 3 h (h) or conditioned medium (g) taken at 3000× revealed nuclear invagination (nuclear perimeter in controls, 35.2 ± 1.2; AMPA, 41.8 ± 1.4; p < 0.05) and irregular clumps of chromatin condensation. Scale bars: c and d, 30 µm; e and f, 10 µm; g and h, 0.5 µm).

AMPA Toxicity Requires Ca2+ Entry through Voltage-Dependent Channels. We reported previously that L-type Ca2+ channel (LTCC) blockers prevent AMPA-induced [Ca2+]i elevations in the perikarya (but not dendrites) of DNs (de Erausquin et al., 1992). The LTCC blocker nimodipine (10 µM) reduced DN death (Fig. 2f) but only partially prevented pruning (in percentage of control length, nimodipine alone, 103.8 ± 10.6; +10 µM AMPA, 58.9 ± 9.0; +30 µM AMPA, 64.5 ± 7.5; +100 µM AMPA, 50.4 ± 6.2). Over 24 h, a small level of activation of Ca2+-permeable GluRAMPA could lead to DNs death. We compared the effects of two GluRAMPA antagonists, the nonselective NBQX (10 µM) and Joro spider toxin analog NAS (30 µM), which selectively blocks Ca2+-permeable receptors. NBQX reduced AMPA toxicity against DNs, whereas NAS was ineffective (Fig. 2a).


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 2.   AMPA toxicity to DNs requires opening of LTCC and is preceded by PS translocation. Cotreatment with 10 µM NBQX, but not 30 µM NAS, caused a left shift in the concentration-response curve of AMPA toxicity to DNs (a). Cotreatment with nimodipine (10 µM) significantly reduced the toxicity of 30 µM AMPA (f) (*, p < 0.01, mean ± S.E.M.). Double-staining of a DN after 100 µM AMPA treatment for 12 h with TH antibodies (b) and Annexin V-Alexa 568 (c). g shows time course of PS translocation as a percentage of the total count of DNs, and overlapping time course of propidium iodide uptake to monitor cell death. PS translocation increased significantly by 6 h (p < 0.001), whereas no significant changes in propidium iodide uptake were detected until 24 h. Spontaneous cell death in untreated cultures was less than 10% (mean ± S.E.M. Scale bar, 30 µm.

Time of Commitment to Die and Mitochodrial Permeability during AMPA Toxicity. Annexin V is a probe for translocation of PS to the outer leaflet of the cell membrane---an event that correlates with commitment to die (Vermes et al., 1995). We assessed PS translocation in DNs using Alexa 568-conjugated Annexin V (Fig. 2b) and TH immunostaining (Fig. 2,c). AMPA (30-100 µM) progressively increased annexin V binding in DNs between 3 and 16 h, before cell death was detected by propidium iodide staining (Fig. 2g). This staining was seldom observed in non-DNs (data not shown).

Because oxidative stress commonly follows Ca2+ overload (Hirsch et al., 1997), we studied ROS production in DNs using the fluorescent probe DHR123. Adding 100 µM AMPA for 10 min increased fluorescence in DNs (Fig. 3a, top) but not in nonDNs (Fig. 3b). Sham washes had no effect. Electron micrographs of DNs after 30 µM AMPA treatment for 3 h showed changes consistent with mitochondrial edema (Fig. 3, d and e). Cytochrome c (Cyt-c) release in DNs was measured by monitoring the redistribution of immunostaining from punctated (mitochondrial) to diffuse (cytosolic). Treatment with 30 µM AMPA for 1 h induced redistribution of Cyt-c staining in TH stained neurons, consistent with release. Pixel distribution was normal after 3-h treatment (Fig. 3f), but at this time, total fluorescence was decreased, suggesting Cyt-c degradation. If mPT opening is required for cell death, preventing it should increase DNs survival. CSA (3 µM) protected DNs against AMPA toxicity (Fig. 3), whereas tacrolimus and calmidazolium were ineffective (Table 1). The inhibitor of the mitochondrial adenine nucleotide translocator, bongkrekic acid, also protected DNs (Fig. 3c). mPT opening may correlate with commitment to die, because addition of CSA 1 or 3 h after onset of 30 µM AMPA failed to provide an equal protection (Fig. 3g).


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 3.   AMPA toxicity requires opening of a mPT. a shows, from left to right, phase contrast, 5,7-DHT, and DHR123 fluorescence images before (3rd) and after (4th) 20-min exposure to 100 µM AMPA alone (top row) or in combination with 10 µM NBQX (bottom row). An increase in DHR123 fluorescence was observed in DNs, which was not seen in other neurons (b) (mean ± S.E.M.; *, p < 0.01 compared with nondopaminergic neurons, n = 20 neurons per group). NBQX prevented the change in fluorescence (a, bottom row, and b). d and e show electron micrographs of TH stained neurons taken at 11,500× in control conditions (d) or after 30 µM AMPA treatment for 3 h. Treatment resulted in swelling of mitochondria and endoplasmic reticulum (e). f shows a quantitative analysis of the distribution of Cyt-c immunostaining before or after 30 µM AMPA for 1 or 3 h. Culture dishes (n = 3/condition) were fixed at the specified times and immunostained for TH and Cyt-c. Pictures of TH-stained neurons were taken blindly with respect to treatment, and the distribution of Cyt-c staining intensity in a region of interest excluding the nucleus was measured with an image analysis system. Punctate staining around the nuclear cup correlated with a distribution of intensities with a mode toward the brightest values. Cyt-c diffusion to the cytosol results in redistribution of pixel intensities along a normal distribution. The difference between these two distributions was statistically significant (chi 2 = 1979, df = 20, p < 0.001). The mPT antagonists bongkrekic acid (10 µM, c; **, p < 0.001 compared with control) and CSA (3 µM, d) resulted in significant protection of DNs after treatment with 30 µM AMPA for 24 h. Addition of 3 µM CSA 1 or 3 h after onset of AMPA treatment resulted in reduced protection, with significant toxicity remaining (p < 0.05; *, p < 0.01 compared with control).


                              
View this table:
[in this window]
[in a new window]
 
TABLE 1
Effect of neuroprotectants on DN survival after AMPA

Values represent mean of three experiments ± S.E.M. In each experiment, four to six wells per treatment were counted. MAP-2 counts did not vary significantly across categories. Cell counts were normalized between experiments to number of MAP-2 cells per well.

AMPA Toxicity Is Mediated by Transcriptional Activation of NFkappa B. Caspases mediate many forms of Cyt-c triggered cell death (Ravagnan et al., 2002). Two nonselective caspase inhibitors, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone and Boc-aspartyl-(OMe)-fluoromethyl ketone, failed to prevent AMPA toxicity to DNs (Table 1). Immunostaining against activated caspase 3 was not detectable in DNs after AMPA treatment (not shown). Cell death triggered by oxidative stress in DNs is mediated by NFkappa B (Hunot et al., 1997). EMSA of NFkappa B DNA-binding proteins in nuclear extracts from cells exposed for 2 h to 30 µM AMPA revealed a band that shifted with anti-NFkappa Bp65 antibody and was eliminated by excess unlabeled oligonucleotide but not by a random sequence oligonucleotide, C-NFkappa B (Fig. 4a). This band was absent in control extracts. When NFkappa B nuclear translocation was assessed by ELISA, 30 µM AMPA treatment for 2 h significantly increased the specific signal; this increase was prevented by the decoy oligonucleotide HPNFkappa B but not by C-NFkappa B (Fig. 4b). NFkappa B is sequestered in the cytosol by the inhibitory protein, Ikappa B; dissociation of Ikappa B from NFkappa B is followed by degradation of Ikappa B and nuclear translocation of NFkappa B (Thanos and Maniatis, 1995). Ikappa B was markedly decreased in cell extracts after 30 µM AMPA for 1 h, with some recovery after 3 h (Fig. 4, c and d). Preventing NFkappa B activation with PDTC (Chung et al., 2000), dexamethasone, or HPNFkappa B, blocked AMPA toxicity (Fig. 4,e-g). C-NFkappa B had a marginally protective effect on cell survival, but did not prevent NFkappa B translocation. Its protective effect may be caused by mild nonspecific protein synthesis inhibition. We controlled for the antioxidant effect of PDTC with the spin trap reagents idebenone and PBN, as well as with the vitamin E analog trolox, all of which failed to protect DNs (Table 1). PDTC may protect neurons through inhibition of NO synthase (Hantraye et al., 1996), but in vitro NO release by itself may increase DNs viability (Mohanakumar et al., 1998). We tested the effect of the NOS inhibitors N-nitro-arginine and N,N-dimethyl-arginine and the NO donor DEA/NO on AMPA toxicity. NOS inhibitors marginally increased DNs survival, and DEA/NO increased AMPA toxicity (Table 1).


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 4.   NFkappa B nuclear translocation and transcriptional activity is required for AMPA toxicity. a shows an example of EMSA for NFkappa B p65 on nuclear extracts of mesencephalic cultures after 3-h treatment with conditioned medium alone (lanes 1-2) or with 30 µM AMPA (lanes 3-4). There is a strong induction of bound p65 after treatment. Lanes 5-6 were run in the presence of excess cold oligonucleotide containing the consensus binding sequence and confirmed the binding specificity. Two other experiments showed identical results. EMSA results were confirmed by a quantitative ELISA-based assay, and the effects of the oligonucleotides HPNFkappa B and C-NFkappa B were assessed (b). Absorbance data represent the average of three separate experiments (*, P < 0.01 versus 100 µM AMPA alone; #, P < 0.05 versus control). Expression of Ikappa Balpha in cell extracts was assessed by Western blot (c and d). A 36-kDa band consistent with IkBalpha was detected in control lines (lanes 1 and 2) and was markedly decreased after 30 µM AMPA for 1 h (lanes 3 and 4) or 3 h (lanes 5 and 6). d shows average optical densities of three separate experiments (*, P < 0.01 versus 30 µM AMPA alone). e shows counts of DNs in cultures exposed to conditioned medium alone, with 30 µM AMPA by itself, or combined with HPNFkappa B (1:10,000 dilution of 3 pg/µl), 10 µM dexamethasone, or 300 µM PDTC. Data represent the average of three experiments (**, P < 0.001 versus control). Examples of TH stained neurons in control conditions (f) and after 30 µM AMPA + HPNFkappa B for 24 h (g) show protection of neurites.

AMPA Toxicity Is Mediated by Activation of p53. RT-PCR products for p53, assessed by a semiquantitative assay normalized to the amount of cyclophilin, were elevated in each of four experiments after 30 µM AMPA treatment for 3 h. HPNFkappa B decreased the amount of p53 mRNA in control wells and prevented the increase induced by AMPA (Fig. 5, a and b). Treatment with 30 µM AMPA for 1 to 3 h increased phos-p53 protein in Western blots (Fig. 5, c and d), and immunohistochemistry revealed that this increase was restricted to DNs (Fig. 5, e and h); phos-p53 expression in DNs trends down after 3 h (Fig. 5i). The p53 inhibitor pifithrin-alpha , which reversibly blocks p53-dependent transcriptional activation and apoptosis (Komarov et al., 1999), protected DNs after 30 µM AMPA treatment for 24 h (Fig. 5j).


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 5.   Induction of p53 oncogene is required for AMPA toxicity. a, Northern blot of mesencephalic cultures extracts after 3-h exposure to conditioned medium (lane 1), 30 µM AMPA (lane 2), HPNFkappa B (1:10,000 dilution of 3 pg/µl, lane 3), and AMPA + HPNFkappa B (lane 4). Optical density averages of four experiments are shown in b (*, p < 0.001 versus control by analysis of variance on ranks). Western blots of phos-p53 are shown in c and d. A 53-kDa band consistent with p53 was detected in control lanes (1-2), which was increased after 30 µM AMPA for 1 h (lanes 3 and 4) or 3 h (lanes 5 and 6). d shows average optical densities of three separate experiments (*, P < 0.01 versus 30 µM AMPA alone). Cellular localization of phos-p53 was assessed by immonocytochemistry (e and h). phos-p53 was not detected in nondopaminergic neurons. TH-stained neurons exposed to conditioned medium (e) did not have detectable phos-p53 immunoreactivity (f) but were stained after 100 µM AMPA for 3 h (g and h). Quantitative image analysis of TH positive neurons demonstrated no change in TH expression but a transient increase in phos-p53 at 3 h (i). (*, p < 0.01). DNs counts in cultures exposed to conditioned medium alone, with 30 µM AMPA by itself, or combined with 10 µM pifithrin-alpha , showed complete protection by the antagonist (j) (**, P < 0.001 versus control).

    Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Excitotoxicity has long been implicated in the pathophysiology of PD (Dunnett and Bjorklund, 1999) but no direct links between experimental and pathological data are available. For instance, hyperactivity of the glutamatergic subthalamic nucleus has been implicated in the generation of symptoms and in the progression of PD through excitotoxicity (Rodríguez et al., 1998). The data presented here suggest that the increase in NFkappa B nuclear translocation observed post-mortem in brains of PD patients may be caused by excitotoxicity.

AMPA toxicity to DNs caused cytosolic vacuolation, mitochondrial swelling, nuclear invagination, irregular chromatin clumping, and a loss of synaptic contacts. These changes are consistent with excitotoxicity but not with neuronal apoptosis (Ishimaru et al., 1999). Abnormal signaling seems also restricted to DNs, but we cannot categorically exclude indirect effects of the treatment on other neuronal phenotypes in the cultures. GluRAMPA stimulation results in a similar [Ca2+]i increase in all neuronal phenotypes in our cultures, but only DNs fail to restore baseline [Ca2+]i after AMPA removal (de Erausquin et al., 1994). LTCC antagonists prevent [Ca2+]i influx to DNs during GluRAMPA stimulation, and blocking Ca2+ release from intracellular stores allows the return of [Ca2+]i to baseline levels (de Erausquin et al., 1994). Now we show that LTCC opening is necessary for AMPA toxicity (Fig. 2f) However, LTCC antagonists had little effect on neurite pruning (data not shown), as expected because of the relative enrichment of N-type channels in neurites of DNs (de Erausquin et al., 1992). Our results also exclude the possibility that low levels of expression of Ca2+-permeable GluRAMPA contribute significantly to toxicity, because the specific antagonist of Ca2+-permeant GluRAMPA, NAS, lacked protective effect.

The selectivity of AMPA toxicity may be because of a greater DNs susceptibility to oxidative stress. In fact, AMPA increased ROS in DNs but not in other neuronal phenotypes (Fig. 3, a and b). This increase in ROS was prevented by NBQX. Cell death can be triggered by Ca2+ overload leading to oxidative stress and mitochondrial release of Cyt-c (Ravagnan et al., 2002). We found evidence of mitochondrial swelling and Cyt-c release soon after exposure of DNs to toxic concentrations of AMPA. Consistent with these findings, the mPT antagonists CSA and bongkrekic acid blocked AMPA toxicity (Fig. 3c). The protective effect of CSA was significantly reduced if treatment began 1 h after onset of AMPA treatment, suggesting that mitochondrial changes occur at the time of commitment to die. This is in agreement with the time of commitment to die assessed by translocation of PS (Fig. 2g). CSA may protect neurons by preventing opening of mPT (Khaspekov et al., 1999; Matsumoto et al., 1999), but also by inhibiting calcineurin (Ankarcrona et al., 1996; Ruiz et al., 2000). Our results indicate that in DNs, AMPA toxicity does not require calmodulin-calcineurin activation, because calmidazolium and tacrolimus failed to afford protection (Table 1).

In DNs, Cyt-c release did not result in caspase 3 activation (Table 1). This result prompts questions concerning the effector mechanism of cell death. Our data indicate that NFkappa B signaling plays a central role in AMPA toxicity to DNs. Two lines of evidence support this view. First, AMPA increases NFkappa B translocation and decreases expression of Ikappa B, both at the time of commitment to die. Second, AMPA toxicity is prevented by three NFkappa B antagonists with different molecular mechanisms of action. PDTC has been shown to prevent or potentiate apoptosis, depending on cell type and culture conditions (Erl et al., 2000). We found that low concentrations of PDTC prevent AMPA toxicity (Fig. 4e). PDTC also has antioxidant properties, is a copper chelator, and inhibits NOS (Chen et al., 2000; Chung et al., 2000), but other antioxidants failed to protect DNs, and NOS inhibitors had limited effect, suggesting that PDTC protects DNs by NFkappa B inhibition. Even though NO release did not affect DNs viability by itself, it significantly potentiated the toxicity of AMPA, suggesting that ADP ribosylation may increase the susceptibility of DNs. Indeed, the ADP ribosylation antagonist benzamide resulted in a degree of protection similar to that of NOS inhibitors (data not shown).

Increased NFkappa B nuclear translocation in PD brains post-mortem has been interpreted as evidence of activation of the TNFalpha pathway (Hunot et al., 1997). Our data suggest that sustained GluRAMPA activation could induce the same result. This finding is potentially very important, if confirmed in vivo, because excitotoxicity may be sustained chronically in PD by subthalamic nucleus hyperactivity. Neuronal NFkappa B is activated by GluRAMPA stimulation (Kaltschmidt et al., 1995), causing cell death in some---including mesencephalic---neuronal phenotypes (Hunot et al., 1997; Schneider et al., 1999; Cassarino et al., 2000) but protecting others against apoptosis (Mattson et al., 2000). In neurons, NFkappa B transcriptional activation causes cell death mediated through p53 (Ryan et al., 2000). Our data suggest that in DNs, transcriptional activation of NFkB causes transcription of p53 mRNA, because HPNFkappa B prevented the increase in p53 mRNA induced by AMPA (Fig. 5). Also, increased phos-p53 expression was restricted to DNs (Fig. 5, c, g, and h) and was necessary for toxicity, because the p53 inhibitor pifithrin-alpha completely prevented DN death. The mechanism of action of pifithrin-alpha has not been completely elucidated, but it seems to act downstream of p53 and may modulate nuclear import or export of p53 or decrease the stability of nuclear p53 (Komarov et al., 1999).

In summary, we have shown that embryonic DNs are selectively susceptible to overactivation of GluRAMPA, resulting in neuronal death mediated through transcriptional activation of NFkappa B. AMPA toxicity, if our findings are confirmed in vivo, may be a good candidate target for neuroprotection of DNs in patients with PD.

    Acknowledgments

We thank J. Xu and C. Hsu for the sequence and samples of HPNKkappa B and E. Costa, J. Olney, E. Johnson, and S. B. Tekkok for their helpful suggestions.

    Footnotes

Received October 22, 2002; Accepted December 20, 2002

This work was partially supported by National Institutes of Health grants (to M.P.G. and L.L.D.) and by a Joint Junior Faculty Award of the United Parkinson Foundation and the Parkinson Disease Foundation (to G.A.d.E.).

Address correspondence to: Gabriel A. de Erausquin, MD, PhD, Departments of Psychiatry and Neurology, CSNSI, Washington University School of Medicine, 660 S. Euclid Ave, Campus Box 8134, St. Louis, MO 63110. E-mail: erausquing{at}neuro.wustl.edu

    Abbreviations

PD, Parkinson disease; DN, dopaminergic neuron; TNF, tumor necrosis factor; NFkappa B, nuclear transcription factor kappa B; GluR, glutamate receptor; AMPA, alpha -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ROS, reactive oxygen species; TH, tyrosine hydroxylase; phos-p53, phosphoprotein p53; MAP2, microtubule associated protein 2; EM, electron microscopy; 5,7-DHT, 5,7-dihydroxitryptamine; DHR123, dihydrorhodamine 123; DTT, dithiothreitol; PMSF, phenylmethylsulfonyl fluoride; EMSA, electrophoretic mobility shift assay; ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction; NBQX, 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide; NAS, 1-napthyl-acetyl spermine trihydrochloride; CSA, cyclosporin A; DEA/NO, sodium 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate; PDTC, pyrrolidine dithiocarbamate; LTCC, L-type Ca2+ channel; Cyt-c, cytochrome c; mPT, mitochondrial permeability transition; NO, nitric oxide NOS, nitric-oxide synthase.

    References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References


0026-895X/03/6304-784-790$3.00
Mol Pharmacol, 63:784-790, 2003
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Sci Aging Knowl EnvironHome page
L. P. Fried, E. C. Hadley, J. D. Walston, A. B. Newman, J. M. Guralnik, S. Studenski, T. B. Harris, W. B. Ershler, and L. Ferrucci
From Bedside to Bench: Research Agenda for Frailty
Sci. Aging Knowl. Environ., August 3, 2005; 2005(31): pe24 - pe24.
[Abstract] [Full Text]


Home page
J. Neurosci.Home page
I. Potrovita, W. Zhang, L. Burkly, K. Hahm, J. Lincecum, M. Z. Wang, M. H. Maurer, M. Rossner, A. Schneider, and M. Schwaninger
Tumor Necrosis Factor-Like Weak Inducer of Apoptosis-Induced Neurodegeneration
J. Neurosci., September 22, 2004; 24(38): 8237 - 8244.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Fujioka, C. Schmidt, G. M. Sclabas, Z. Li, H. Pelicano, B. Peng, A. Yao, J. Niu, W. Zhang, D. B. Evans, et al.
Stabilization of p53 Is a Novel Mechanism for Proapoptotic Function of NF-{kappa}B
J. Biol. Chem., June 25, 2004; 279(26): 27549 - 27559.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Erausquin, G. A.
Right arrow Articles by Dugan, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Erausquin, G. A.
Right arrow Articles by Dugan, L. L.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics